AFAP1 and cancer: Liu et al. [11] performed meta-analysis including a total of 1017 cancer patients from eight studies, and found cancer patients with high AFAP1-AS1 expression had a shorter recurrence-free survival, a worse progression-free survival, and a poorer overall survival than those with low AFAP1-AS1 expression.